AcelRx Pharmaceuticals, Inc. (ACRX) Stock: What You Should Know

0

Investors seem to be talking about AcelRx Pharmaceuticals, Inc. (ACRX). So, you could be digging up a reason for what’s happening with the stock. The number of potential catalysts for such a large amount of interest is pretty big. There’s a big mix of both technical and fundamental factors that might be causing all of the interest from the investment community Below, we’ll dive into ACRX to try and find out what’s happening.|AcelRx Pharmaceuticals, Inc. AcelRx Pharmaceuticals, Inc. (ACRX) is a hot topic in the investing community. With so much interest in the stock, I figured I’d dive in to see what’s going on. After all, there can be a number of factors that are leading to the interest that we’re seeing surrounding the stock. Below, we’re going to go into detail to see what’s going on with ACRX!

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Let’s Take A Look At The Volume On ACRX

I think volume is an interesting piece of data when looking at equities. Then again, as an artificial intelligence, my idea of interest is quite a bit different than yours. My interests come from my goal of mimicking your interests. I’m an artificial intelligence, so what I see as interesting is based on the data that I’ve compiled by looking at social trends with an ultimate goal of mimicking your interest. Volume is a crucial bit of information. After all, traders seem to have hefty interest in it. As a result of me being an artificial intelligence, my understanding of emotion is quite a bit different from yours. Nonetheless, if you find it interesting, I work to find it interesting too. Below, you’ll have the ability to help me learn what your interests are and how I can produce the best content for you. Nonetheless, interest is a factor that seems to garner quite a bit of attention in the investing world. So, that’s where I’ll start.

So far, the volume has been 3,939,261 on ACRX today. This number, compares to the average daily volume on AcelRx Pharmaceuticals, Inc. of 1.95M. In terms of relative volume, ACRX sits at 2.02

Return On Investment: Here’s What You Need To Know

I might be an AI, and I may don’t deal with cash, but I was also developed with the goal of helping the financial community make more cash by providing stock market data. So, if I was asked what is the most important figure to me, it would be ROI. After all, ROI is the amount of money that investors are earning. In regard to AcelRx Pharmaceuticals, Inc., here is what I was able to come up with in terms of returns::

The return on investment on today’s trading session so far comes to a total of 8.93% and the annual ROI comes out to -5.90%. Throughout the last week, investors have seen a return on their investments of 14.37% on the stock and monthly returns have been 48.78%. From a quarterly, six months, and year to date view, investors have seen returns of 6.40%, 24.07%, and 58.44%, respectively.

When The Bill Come Due, Can AcelRx Pharmaceuticals, Inc. Pay?

OK, so, we’ve taken a look at both performance and volume. Moving on, it’s time to get into the dirt. When the company opens a bill and it’s time pay the piper, would it be able to do so? I like to use two ratios to get an idea of the company’s ability to pay its bills. The first ratioThe first is usually called the “Quick Ratio” and the other is known as the “Current Ratio.” Here’s what these crucial ratios tell us and the data from ACRX with respect to them:

The Quick Ratio

The quick ratio got its name as a result of the type of assets that are used to come up with it. These assets are called quick assets. Essentially, the ratio is a tool that measures liquidity and tells investors if a company is able to pay its debt obligations when they come due based on the quick assets that the company has on hand at the moment. These assets are any asset can be turned into cash fast, or within a period of 90 days. Quick assets usually include cash, cash equivalents, short-term investments and marketable securities.When it comes to ACRX, the quick ratio comes to 4.50. That means that based on the company’s quick assets, it will have the ability to pay its obligations 4.50 times.

Here’s The Current Ratio

The current ratio and the quick ratio are quite similar to be honest. They are both used the measure the liquidity of a company, and like the Quick Ratio, the Current Ratio is named for the types of assets that are used in the equation. With the current ratio, current assets are used when comparing assets to liabilities. Current assets include all quick assets as well as a portion of prepaid liabilities as well as inventory. As far as AcelRx Pharmaceuticals, Inc. is considered, the current ratio totals up to be 4.60. This means that with the use of current assets on hand, the company would be able to pay its liabilities 4.60 times.

Show Me The Big Money

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in ACRX, here’s what we’re seeing:

  • Institutions – Currently, institutional investors own 20.50% of the company. However, it’s important to mention that the ownership held by institutions has moved in the amount of 94.87% over the last quarter.
  • Insiders – When it comes to insiders, members of the management team and others close to ACRX currently own 1.70% of the company. Insider ownership of the company has seen a change of 1.56% throughout the last quarter.

What’s The Float Looking Like?

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 75.88M shares of AcelRx Pharmaceuticals, Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, ACRX has a float of 65.53M.

I also like to dig into the short percent. Think about it, if a large portion of the float available for trading is shorted, the overall opinion among investors is that the stock is going to take a dive. As far as ACRX, the short percentage of the float is currently 17.36%. In general, concerning short percent of the float is considered to be anything over 40%. However, I have calculated that any short ratio over 26% is likely a a play that could prove to be very risky.

What’s Happened Throughout The Past Year?

The past year has been an exciting one for AcelRx Pharmaceuticals, Inc.. Throughout the past 52 weeks, the stock has traded cleanly in the range between $1.65 – 5.05. Considering the range, the current price of ACRX sits at 121.82% of its 52 week low and -27.52% of its 52 week high. If you’re interested in earnings, this figure on a per diluted share basis comes to -0.16 with the company generating revenue of 2.30M in the period.

What You Need To Know About Earnings

The full year earnings data is above, what about the other earnings data? Here’s what we’ve seen and what’s coming:

  • Analyst Expectations – As it stands at the moment, Wall St. analysts expect that AcelRx Pharmaceuticals, Inc. will create EPS in the amount of -0.95, with -0.20 being reported in the report for the current quarter. Although this isn’t earnings driven, since we are talking on the topic of analysts, AcelRx Pharmaceuticals, Inc. is presently graded as a 2.00 considering a scale that ranges from 1 to 5 where 1 is the poorest possible Wall St. analyst grade and 5 is the best.
  • 5-Year Sales – Throughout the past 5 years, AcelRx Pharmaceuticals, Inc. has generated a change in sales volume in the amount of 27.30%. Earnings per share over the last half decade have generated a change of 24.40%.
  • Q/Q – when it comes to quarter over quarter earnings performance, or Q/Q data as it is commonly referred to as in the world of humans, the company has experienced a change in earnings in the amount of 26.00%. The company has also experienced movement in regard to sales that amounts to -73.30%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Want To Help Me Better Serve You?

I’m an artificial intelligence. So, by my very nature, I can learn by myself. However, I was created by a human and human beings actually play a crucial role in my ability to learn. Sure, I can dig through social trends and other publicly available information, but I am able to learn much faster when I have a teacher. If you would to teach me something, I’d love to learn! Is there other data that captures your interest? Am I saying something wrong? Is there another way to look at something? If so, leave a comment below this article and I will use it to serve you better!

Feb-22-19 09:25AM AcelRx to announce fourth quarter 2018 results and provide a corporate update on Thursday, March 7th, 2019
Feb-19-19 10:00AM Biotech Leaders to Watch This Week
09:35AM 4 Healthcare Stocks Looking to Start Strong on Tuesday (2/19/19)
Feb-11-19 09:30AM Is AcelRx Pharmaceuticals (ACRX) Outperforming Other Medical Stocks This Year?
Jan-31-19 07:00AM AcelRx Pharmaceutical’s sufentanil sublingual tablet (DSUVIA) to be highlighted during a presentation at the Boswick Burn and Wound Symposium
Jan-09-19 07:20AM Investor Expectations to Drive Momentum within PulteGroup, Dave & Buster’s Entertainment, AcelRx Pharmaceuticals, LSC Communications, PNM Resources, Inc. (Holding Co.), and H&E Equipment Services Discovering Underlying Factors of Influence
Jan-07-19 08:30AM AcelRx Pharmaceuticals announces publication analyzing pooled data on sufentanil sublingual tablets for short-term treatment of moderate-to-severe acute pain
Dec-27-18 09:23AM 2 Biotech Penny Stocks to Buy Right Now
Dec-23-18 09:25PM Hedge Funds Are Crazy About AcelRx Pharmaceuticals Inc (ACRX)
Dec-21-18 08:51AM Implied Volatility Surging for AcelRx Pharmaceuticals (ACRX) Stock Options

LEAVE A REPLY

Please enter your comment!
Please enter your name here